Advertisement


Margaret A. Tempero, MD, on Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options

NCCN 2022 Annual Conference

Advertisement

Margaret A. Tempero, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the most effective ways to use the regimens available to treat patients with pancreatic cancer (FOLFIRINOX [fluorouracil, leucovorin, irinotecan, and oxaliplatin] and gemcitabine plus albumin-bound paclitaxel). Dr. Tempero also reviews the upfront use of chemotherapy for resectable disease, and ways to modify these therapies to make them more tolerable for patients. Looking ahead, she expresses hope for the new drugs under development, which may inactivate RAS, a major driver of the disease.



Related Videos

Bladder Cancer

Thomas W. Flaig, MD, on Bladder Cancer: New Treatment Options

Thomas W. Flaig, MD, of the University of Colorado Cancer Center, discusses the rapidly changing treatment landscape for patients with bladder cancer, including PD-1 and PD-L1 inhibitors now approved for urothelial carcinoma; a category 1 indication for pembrolizumab in metastatic disease, post-platinum treatment and for non–muscle-invasive bladder cancer; enfortumab vedotin-ejfv for subsequent-line use; and erdafitinib for those with select FGFR mutations.

Prostate Cancer

Julio M. Pow-Sang, MD, on Nonmetastatic Prostate Cancer: Update on Best Management Practices

Julio M. Pow-Sang, MD, of Moffitt Cancer Center, discusses the treatment landscape for localized prostate cancer and its heterogeneity, the critical importance of stratifying risk to determining treatment options, and the continued improvement of therapy in the field.

Lymphoma

Ann S. LaCasce, MD, MMSc, on Relapsed/Refractory Indolent Follicular Lymphoma: Management Updates

Ann S. LaCasce, MD, MMSc, of Dana-Farber Cancer Institute, discusses the various agents available to treat patients with indolent B-cell lymphomas: lenalidomide plus rituximab, which has a superior progression-free survival profile compared with rituximab monotherapy; the PI3K inhibitors copanlisib and umbralisib, which have similar efficacy yet distinct side-effect profiles; tazemetostat, which is active in both EZH2-mutant and Warthin’s tumor disease; and CAR T-cell therapy, which shows early activity.

Colorectal Cancer

Smitha S. Krishnamurthi, MD, on Colorectal Cancer: Treatment Updates

Smitha S. Krishnamurthi, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses prognostic assays for localized colon cancer, the potential clinical uses and current limitations of prognostic assays for stage II to III disease, and checkpoint inhibitor therapy for metastatic colorectal cancer.

Colorectal Cancer

Reid M. Ness, MD, MPH, on Colorectal Cancer: Updates in Screening Recommendations

Reid M. Ness, MD, MPH, of Vanderbilt-Ingram Cancer Center, discusses significant updates to the NCCN Clinical Practice Guidelines in Oncology for colorectal cancer screening: lowering the age from 50 to 45 for the initiation of average-risk screening for all combinations of race, ethnicity, and sex; and extending the surveillance interval from 5 to 7–10 years following the identification of one to two low-risk adenomas.

Advertisement

Advertisement



Advertisement